
Please try another search
Name | Net % | Long % | Short % |
---|---|---|---|
Cash | 0.900 | 0.900 | 0.000 |
Shares | 99.100 | 99.100 | 0.000 |
Ratios | Value | Category Average |
---|---|---|
P/E Ratio | 26.264 | 21.986 |
Price to Book | 3.991 | 3.687 |
Price to Sales | 4.031 | 2.893 |
Price to Cash Flow | 18.566 | 16.066 |
Dividend Yield | 1.543 | 2.120 |
5 Years Earnings Growth | 8.484 | 9.465 |
Name | Net % | Category Average |
---|---|---|
Healthcare | 25.490 | 14.737 |
Technology | 22.000 | 17.357 |
Industrials | 20.820 | 26.198 |
Basic Materials | 10.950 | 6.855 |
Consumer Cyclical | 8.770 | 11.044 |
Consumer Defensive | 8.660 | 7.793 |
Financial Services | 3.300 | 11.062 |
Number of long holdings: 38
Number of short holdings: 0
Name | ISIN | Weight % | Last | Change % | |
---|---|---|---|---|---|
ASML Holding | NL0010273215 | 5.87 | 596.20 | -1.03% | |
Schneider Electric | FR0000121972 | 5.33 | 214.75 | -2.07% | |
Air Liquide | FR0000120073 | 4.96 | 172.86 | +0.36% | |
Alcon | CH0432492467 | 4.58 | 70.60 | -0.56% | |
Relx | GB00B2B0DG97 | 4.19 | 3,820.00 | -2.15% | |
EssilorLuxottica | FR0000121667 | 4.19 | 253.40 | -1.09% | |
Novo Nordisk B | DK0062498333 | 3.79 | 305.9 | -2.27% | |
Novozymes AS | DK0060336014 | 3.61 | 426.9 | +1.07% | |
Amadeus | ES0109067019 | 3.49 | 70.340 | +0.11% | |
SAP | DE0007164600 | 3.44 | 246.600 | +0.76% |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
Europe EUR Acc | 4.16B | -2.61 | 7.35 | 7.55 | ||
Europe EUR Dis | 4.16B | -2.62 | 7.34 | 7.54 | ||
IE00BYYLQ421 | 958.2M | 17.12 | 5.17 | 11.09 | ||
IE00BJ625P22 | 958.2M | 17.14 | 5.22 | 11.12 | ||
IE00B6X2JP23 | 978.07M | -4.98 | 14.24 | 12.04 |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review